On Thursday, Willis Towers Watson received a positive adjustment to its Relative Strength (RS) Rating, from 66 to 71.
IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Willis Towers Watson can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Willis Towers Watson is now considered extended and out of buy range after clearing a 269.98 buy point in a first-stage saucer with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
In terms of top and bottom line numbers, Willis Towers Watson has posted rising EPS growth in each of the last two reports. Sales growth has also increased during the same period.
The company earns the No. 5 rank among its peers in the Insurance-Brokers industry group. Ryan Specialty Holdings is the top-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
